TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18654759

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 280

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 280
Study: 15825788

Group type: EXPERIMENTAL
Intervention: Elastomeric rings
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ligature wires
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 21
Study: 12187499

Group type: COMPARATOR
Intervention: Antiretrovirals (d4T, ddI, EFV, ABC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Antiretrovirals + Hydroxyurea (HU)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Antiretrovirals + Hydroxyurea (HU) + Interleukin-2 (IL-2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Antiretrovirals alone or in combination with HU and IL-2
Number of subjects: 69
Study: 10609719

Group type: EXPERIMENTAL
Intervention: Transvaginal sonography, Pipelle endometrial biopsy, outpatient hysteroscopy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Hysteroscopy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Outpatient Pipelle
Number of subjects: 400

Group type: COMPARATOR
Intervention: Outpatient procedures
Number of subjects: 400
Study: 8695837

Group type: EXPERIMENTAL
Intervention: Quinine (30 mg/kg/d, days 1 to 5; continuous intravenous infusion beginning 24 hours before mitoxantrone infusion)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (mitoxantrone 12 mg/m2/d, days 2 to 5 and cytarabine 1 g/m2/12 h, days 1 to 5)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Quinine group
Number of subjects: 315
Study: 1752115

Group type: EXPERIMENTAL
Intervention: Epoetin beta (intravenous)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epoetin beta (subcutaneous)
Number of subjects: 18
Study: 6122483

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Intralipid (soya oil) clearance
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: initially reduced HDL cholesterol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: initially raised free fatty acid concentrations
Number of subjects: 53
Study: 30679284

Group type: EXPERIMENTAL
Intervention: Access to mobile phone
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Willingness to receive mobile phone-based health services
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Educational status
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Route of medication
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Transportation mechanism
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Travel time to health facility
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Current use of mobile phone as appointment reminder
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Locking mobile phone with passwords
Number of subjects: 423
Study: 28596043

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Etanercept 50 mg
Number of subjects: 1862
Study: 25601538

Group type: EXPERIMENTAL
Intervention: Ecallantide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23900311

Group type: EXPERIMENTAL
Intervention: MTHFR C677T T-allele carriers with traumatic childhood events (T+ and TCE+)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: MTHFR C677T non-carriers with traumatic childhood events (T- and TCE+)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: MTHFR C677T T-allele carriers without traumatic childhood events (T+ and TCE-)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: MTHFR C677T non-carriers without traumatic childhood events (T- and TCE-)
Number of subjects: 789

Group type: COMPARATOR
Intervention: MTHFR genotype and TCEs interaction on depressive symptomatology in healthy individuals
Number of subjects: 789
Study: 21107436

Group type: EXPERIMENTAL
Intervention: Ischemic heart disease (IHD)
Number of subjects: 24379

Group type: EXPERIMENTAL
Intervention: Ischemic stroke
Number of subjects: 24379

Group type: EXPERIMENTAL
Intervention: Presence of hypertension
Number of subjects: 24379

Group type: EXPERIMENTAL
Intervention: Presence of diabetes mellitus
Number of subjects: 24379

Group type: EXPERIMENTAL
Intervention: Presence of hypercholesterolemia
Number of subjects: 24379
Study: 19501900

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (n=2220)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Active control (combination of metformin and sulfonylurea, n=2227)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Active control (n=2227)
Number of subjects: 4447
Study: 18219833

Group type: EXPERIMENTAL
Intervention: Santana apple
Number of subjects: 15

Group type: COMPARATOR
Intervention: Golden Delicious apple
Number of subjects: 15

Group type: COMPARATOR
Intervention: Topaz apple
Number of subjects: 15
Study: 12579025

Group type: EXPERIMENTAL
Intervention: One-step povidone-iodine topical gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Two-step iodophor scrub followed by povidone-iodine paint
Number of subjects: 50
Study: 10594395

Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 94

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 94
Study: 8694726

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 184

Group type: COMPARATOR
Intervention: 0.5% timolol maleate twice daily
Number of subjects: 184
Study: 1874212

Group type: EXPERIMENTAL
Intervention: Alfentanil 0.25 microgram kg‐1 min‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alfentanil 0.50 microgram kg‐1 min‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alfentanil 0.75 microgram kg‐1 min‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propofol 20‐200 mg h‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of propofol and alfentanil
Number of subjects: 44
Study: 6128776

Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg pindolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alpha blockade (preceding all interventions)
Number of subjects: 10
Study: 31677181

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) plus metformin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo plus metformin (Plac/Met)
Number of subjects: 10
Study: 31358588

Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT); specific details on dosage and duration not provided.
Number of subjects: 1399
Study: 28648417

Group type: EXPERIMENTAL
Intervention: HFRT + SCT
Number of subjects: 70

Group type: COMPARATOR
Intervention: SCT-alone
Number of subjects: 70
Study: 26209863

Group type: EXPERIMENTAL
Intervention: ENG implant inserted within 48 h after delivery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (absence of contraceptive method)
Number of subjects: 24
Study: 23819701

Group type: EXPERIMENTAL
Intervention: CHANGE! intervention
Number of subjects: 318
Study: 22168507

Group type: EXPERIMENTAL
Intervention: Computerised cognitive behavioural therapy (CCBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 19448579

Group type: EXPERIMENTAL
Intervention: SenSura appliances
Number of subjects: 148

Group type: COMPARATOR
Intervention: Reference appliances
Number of subjects: 148
Study: 17135811

Group type: EXPERIMENTAL
Intervention: Quality of Life‐AD
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Quality of Life Activity Inventory
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: SF‐36
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: SF‐12
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Satisfaction with Life Scale
Number of subjects: 644
Study: 15123224

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 15
Study: 10510951

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8541472

Group type: EXPERIMENTAL
Intervention: 'Theory of mind' condition
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control conditions (visual and semantic attributes of known objects)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Condition inferring function of an unfamiliar object from its form
Number of subjects: 9
Study: 1945579

Group type: EXPERIMENTAL
Intervention: PRP-T mixed with DTP vaccine in a single syringe (Group A)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: PRP-T given in one arm and DTP in the other arm (Group B)
Number of subjects: 278

Group type: COMPARATOR
Intervention: DTP given in one arm and placebo in the other (Group C)
Number of subjects: 278
Study: 7021072

Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 900 mg soluble aspirin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 19
Study: 31449168

Group type: EXPERIMENTAL
Intervention: Bevacizumab (36-144 μg/dl forearm volume per minute) for 15-60 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bradykinin (100 and 1000 pmol/min) with and without bevacizumab (144 μg/dl forearm volume per minute)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BQ-123 (10 nmol/min) with bradykinin
Number of subjects: 10
Study: 30590565

Group type: EXPERIMENTAL
Intervention: Balloon-expandable valves (BE)
Number of subjects: 12381

Group type: COMPARATOR
Intervention: Self-expandable valves (SE)
Number of subjects: 12381

Group type: EXPERIMENTAL
Intervention: New-generation balloon-expandable valves (BE)
Number of subjects: 12381

Group type: COMPARATOR
Intervention: New-generation self-expandable valves (SE)
Number of subjects: 12381
Study: 30062716

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/day for 24 weeks)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 26634323

Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 1162
Study: 25121719

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22978098

Group type: EXPERIMENTAL
Intervention: Yupei Qisun Sequential Method (YQSM) combined with IVF/ICSI
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVF/ICSI alone (Control)
Number of subjects: 60
Study: 20139233

Group type: EXPERIMENTAL
Intervention: DHEA (75 mg/d) in elderly men
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Testosterone (5 mg/d) in elderly men
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/d) in elderly women
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo in elderly men
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo in elderly women
Number of subjects: 144
Study: 17438317

Group type: EXPERIMENTAL
Intervention: Chondroitin
Number of subjects: 3846
Study: 15625147

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 microg every 6 hours x 2 doses
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dinoprostone gel 0.5 mg every 6 hours x 2 doses
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Dinoprostone pessary 10 mg x 1 dose for 12 hours
Number of subjects: 111
Study: 12383570

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (10 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10432918

Group type: EXPERIMENTAL
Intervention: 0.22-micron filter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette filter
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20-micron filter
Number of subjects: 0
Study: 7587005

Group type: EXPERIMENTAL
Intervention: Pears
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Apples
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oranges
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Grapes
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Plums
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Peaches
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Apricots
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bananas
Number of subjects: 61
Study: 31243258

Group type: COMPARATOR
Intervention: Single application of platelet-rich plasma (PRP)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Triple application of platelet-rich plasma (PRP)
Number of subjects: 35
Study: 26677237

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 24021691

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 463
Study: 21278555

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended release epidural morphine (DepoDur)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both CFNB and DepoDur
Number of subjects: 0
Study: 19038468

Group type: EXPERIMENTAL
Intervention: Concomitant and adjuvant short-term hormonal treatments with curative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dummy run procedure combined with individual case review
Number of subjects: 0
Study: 17939933

Group type: EXPERIMENTAL
Intervention: Management strategies for mucocutaneous HSV-induced disease
Number of subjects: 0
Study: 15491386

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 13
Study: 11557912

Group type: EXPERIMENTAL
Intervention: Everolimus as part of a cyclosporine-prednisone immunosuppressive regimen
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Everolimus with concomitant erythromycin or azithromycin
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Everolimus with concomitant itraconazole
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Everolimus in black patients
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Everolimus adjusted for covariates
Number of subjects: 673
Study: 9632444

Group type: EXPERIMENTAL
Intervention: Invasive management (routine coronary angiography followed by myocardial revascularization)
Number of subjects: 920

Group type: COMPARATOR
Intervention: Conservative management (medical therapy and noninvasive testing, with subsequent invasive management if indicated)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 920

Group type: COMPARATOR
Intervention: Overall mortality during follow-up
Number of subjects: 920
Study: 8152446

Group type: EXPERIMENTAL
Intervention: Ursodiol (13 to 15 mg per kilogram of body weight per day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 3349297

Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (ASPTV)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 91
Study: 30452732

Group type: EXPERIMENTAL
Intervention: Nicotine Mouth Spray (NMS)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1198
Study: 29072086

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Education intervention (Control)
Number of subjects: 24
Study: 28406746

Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Number of subjects: 1503

Group type: COMPARATOR
Intervention: NBP607-Y
Number of subjects: 1503

Group type: COMPARATOR
Intervention: NBP607-V
Number of subjects: 1503
Study: 26242122

Group type: EXPERIMENTAL
Intervention: Integrative medicine treatment group (anti‐virus Western medicine plus CQG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Western medicine treatment group (treated with anti‐virus Western medicine)
Number of subjects: 30
Study: 22966096

Group type: EXPERIMENTAL
Intervention: Intralesional recombinant human epidermal growth factor (rhEGF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 20935586

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Single vision lenses (SVLs)
Number of subjects: 85
Study: 18394900

Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent Haemodialysis (IHD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid therapies
Number of subjects: 0
Study: 16878257

Group type: EXPERIMENTAL
Intervention: Genotyping-based treatment switch (group 1)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard of care (group 2)
Number of subjects: 74
Study: 12804345

Group type: EXPERIMENTAL
Intervention: Aerobic exercises (walking or stationary cycling) or a combination of aerobic plus spinal flexibility exercises for 1 hour 3 days a week for 3 months
Number of subjects: 114
Study: 10678643

Group type: EXPERIMENTAL
Intervention: Tidal breathing method (PC20 value of <=8.0 mg x mL(‐1))
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mefar dosimeter protocol (PD20 value of <=0.5 mg)
Number of subjects: 47
Study: 8888830

Group type: EXPERIMENTAL
Intervention: yoked base-up and base-in prism combined with plus power lenses
Number of subjects: 30
Study: 1324645

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amoxicillin (500 mg three times daily for 5 days)
Number of subjects: 50
Study: 6370581

Group type: EXPERIMENTAL
Intervention: 4% aqueous sodium lauryl sulfate (SLS) solution applied for 24 hours
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5% aqueous sodium lauryl sulfate (SLS) solution applied for 24 hours
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2% aqueous sodium lauryl sulfate (SLS) solution applied for two successive 24-hour applications
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3% aqueous sodium lauryl sulfate (SLS) solution applied for two successive 24-hour applications
Number of subjects: 36
Study: 30719580

Group type: EXPERIMENTAL
Intervention: Minodronic acid
Number of subjects: 3229

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 3229
Study: 29953013

Group type: EXPERIMENTAL
Intervention: Yokukansankachimpihange (YKSCH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 27141834

Group type: EXPERIMENTAL
Intervention: LINC intervention
Number of subjects: 349

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 349
Study: 24973361

Group type: EXPERIMENTAL
Intervention: ASXL2 mutations in t(8;21) AML patients
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ASXL1 mutations in t(8;21) AML patients
Number of subjects: 110

Group type: COMPARATOR
Intervention: ASXL1/2 wild-type counterparts
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Overall survival comparison
Number of subjects: 110
Study: 23079354

Group type: EXPERIMENTAL
Intervention: Training in initiation to learning reading (experimental group)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 144
Study: 21144223

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 micrograms, once daily for 4 weeks
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 17685689

Group type: EXPERIMENTAL
Intervention: Low-intensity training (Z1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moderately high-intensity training (Z2)
Number of subjects: 12
Study: 15379010

Group type: EXPERIMENTAL
Intervention: 1 alias
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: 5 aliases
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: 9 aliases
Number of subjects: 540

Group type: COMPARATOR
Intervention: No alias information
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: All 9 aliases with relationship information
Number of subjects: 540

Group type: COMPARATOR
Intervention: All 9 aliases without relationship information
Number of subjects: 540
Study: 11380067

Group type: EXPERIMENTAL
Intervention: 250 mg dose of metronidazole
Number of subjects: 24
Study: 9685816

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 2656

Group type: EXPERIMENTAL
Intervention: iopentol
Number of subjects: 2656

Group type: COMPARATOR
Intervention: ionic CMs
Number of subjects: 2656

Group type: COMPARATOR
Intervention: non-ionic CMs
Number of subjects: 2656
Study: 7978086

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CB) for ASPs
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Relationship Enhancement Treatment for ASPs
Number of subjects: 149

Group type: COMPARATOR
Intervention: Non-ASPs treated with any method
Number of subjects: 149
Study: 2791543

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS) - different qualities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS) - high purity
Number of subjects: 0
Study: 7767

Group type: EXPERIMENTAL
Intervention: Formula 2 (3.0 gm of protein per 100 ml, 60:40)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Formula 4 (3.0 gm of protein per 100 ml, 18:82)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Formula 1 (1.5 gm of protein per 100 ml, 60:40)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Formula 3 (1.5 gm of protein per 100 ml, 18:82)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Banked human milk (BM)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Casein‐predominant formulas (F3, F4)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Whey protein‐predominant formulas (F1, F2)
Number of subjects: 106
Study: 30658003

Group type: EXPERIMENTAL
Intervention: Surgical positioning software
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fluoroscopy (Control)
Number of subjects: 200
Study: 28902012

Group type: EXPERIMENTAL
Intervention: Oral Voriconazole (VCZ) 200 mg twice a day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral Ketoconazole (KCZ) 200 mg twice a day
Number of subjects: 50